These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 17579933)

  • 1. Health technology assessment and ill-structured problems: a case study concerning the drug mebeverine.
    Moret-Hartman M; van der Wilt GJ; Grin J
    Int J Technol Assess Health Care; 2007; 23(3):316-23. PubMed ID: 17579933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment patterns and health care costs of mebeverine-treated IBS patients: a case-control study.
    Goettsch WG; van den Boom G; Breekveldt-Postma NS; Smout AJ; Herings RM
    Pharmacoepidemiol Drug Saf; 2004 Nov; 13(11):803-10. PubMed ID: 15386693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome.
    Darvish-Damavandi M; Nikfar S; Abdollahi M
    World J Gastroenterol; 2010 Feb; 16(5):547-53. PubMed ID: 20128021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine.
    Lee KJ; Kim NY; Kwon JK; Huh KC; Lee OY; Lee JS; Choi SC; Sohn CI; Myung SJ; Park HJ; Choi MK; Bak YT; Rhee PL
    Neurogastroenterol Motil; 2011 Dec; 23(12):1098-104. PubMed ID: 21920001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 'The problem is small enough, the problem is big enough': a qualitative study of health technology assessment and public policy on drug funding decisions for children.
    Denburg AE; Giacomini M; Ungar WJ; Abelson J
    Int J Equity Health; 2020 Mar; 19(1):45. PubMed ID: 32228588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
    Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
    Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of treatment outcome after cognitive behavior therapy and antispasmodic treatment for patients with irritable bowel syndrome in primary care.
    Reme SE; Kennedy T; Jones R; Darnley S; Chalder T
    J Psychosom Res; 2010 Apr; 68(4):385-8. PubMed ID: 20307706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive behaviour therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomised controlled trial.
    Kennedy T; Jones R; Darnley S; Seed P; Wessely S; Chalder T
    BMJ; 2005 Aug; 331(7514):435. PubMed ID: 16093252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Who's afraid of institutionalizing health technology assessment (HTA)?: Interests and policy positions on HTA in the Czech Republic.
    Löblová O
    Health Econ Policy Law; 2018 Apr; 13(2):137-161. PubMed ID: 29108525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy and safety of trimebutine versus mebeverine in the treatment of irritable bowel syndrome.
    Rahman MZ; Ahmed DS; Mahmuduzzaman M; Rahman MA; Chowdhury MS; Barua R; Ishaque SM
    Mymensingh Med J; 2014 Jan; 23(1):105-13. PubMed ID: 24584382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of mebeverine with high-fibre dietary advice and mebeverine plus ispaghula in the treatment of irritable bowel syndrome: an open, prospectively randomised, parallel group study.
    Chapman ND; Grillage MG; Mazumder R; Atkinson SN
    Br J Clin Pract; 1990 Nov; 44(11):461-6. PubMed ID: 2177997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mediators of change in cognitive behaviour therapy and mebeverine for irritable bowel syndrome.
    Reme SE; Stahl D; Kennedy T; Jones R; Darnley S; Chalder T
    Psychol Med; 2011 Dec; 41(12):2669-79. PubMed ID: 21477419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients.
    Jones RH; Holtmann G; Rodrigo L; Ehsanullah RS; Crompton PM; Jacques LA; Mills JG
    Aliment Pharmacol Ther; 1999 Nov; 13(11):1419-27. PubMed ID: 10571597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mebeverine alters small bowel motility in irritable bowel syndrome.
    Evans PR; Bak YT; Kellow JE
    Aliment Pharmacol Ther; 1996 Oct; 10(5):787-93. PubMed ID: 8899088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of cognitive behaviour therapy in addition to mebeverine for irritable bowel syndrome.
    McCrone P; Knapp M; Kennedy T; Seed P; Jones R; Darnley S; Chalder T
    Eur J Gastroenterol Hepatol; 2008 Apr; 20(4):255-63. PubMed ID: 18334867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integration of health technology assessment recommendations into organizational and clinical practice: A case study in Catalonia.
    Gagnon MP; Sánchez E; Pons JM
    Int J Technol Assess Health Care; 2006; 22(2):169-76. PubMed ID: 16571192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of mebeverine in irritable bowel syndrome. A Position paper of the Romanian Society of Neurogastroenterology based on evidence.
    Dumitrascu DL; Chira A; Bataga S; Diculescu M; Drug V; Gheorghe C; Goldis A; Nedelcu L; Porr PJ; Sporea I;
    J Gastrointestin Liver Dis; 2014 Dec; 23(4):431-5. PubMed ID: 25532003
    [No Abstract]   [Full Text] [Related]  

  • 18. Diffusion and use of health technology assessment in policy making: what lessons for decentralised healthcare systems?
    Ciani O; Tarricone R; Torbica A
    Health Policy; 2012 Dec; 108(2-3):194-202. PubMed ID: 23093020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life of patients with irritable bowel syndrome is low compared to others with chronic diseases.
    ten Berg MJ; Goettsch WG; van den Boom G; Smout AJ; Herings RM
    Eur J Gastroenterol Hepatol; 2006 May; 18(5):475-81. PubMed ID: 16607141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Irritable bowel syndrome-an unbeloved problem].
    Heldwein W; Eisenlohr H
    MMW Fortschr Med; 2008 Mar; 150(13):41-3. PubMed ID: 18522357
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.